Overview of Chronic Lymphocytic Leukemia

Impact on Older Adults

Chronic lymphocytic leukemia (CLL) significantly affects older adults, particularly those around or after middle age. This type of cancer originates in blood stem cells, leading to an overproduction of white blood cells in the bone marrow. The disease can impact red blood cells, white blood cells, and platelets, making it the most common form of leukemia among adults. While rare in children, CLL can occasionally occur in individuals under the age of 40. In the United States, the average age for a CLL diagnosis is approximately 70 years.

Statistics and Risk Factors

According to estimates from the American Cancer Society for 2019, around 20,000 new cases of CLL were reported in the U.S., with approximately 4,000 deaths attributed to the condition. The lifetime risk of developing CLL is nearly 1 in 175. Factors such as being middle-aged or older, being male, being white, or having a family history of lymphoid cancer can elevate the risk of this disease.

Symptoms and Current Treatments

In many cases, CLL progresses slowly, often without noticeable signs or symptoms, and is typically identified through routine blood tests. Currently, chemotherapy remains the primary treatment for both intermediate and high-risk CLL to manage blood cell counts, alleviate anemia, and reduce lymph node size. However, chemotherapy is generally not recommended for patients in poor health, highlighting the need for effective targeted therapies for this patient demographic.

Advancements in CLL Treatment

Research on Ibrutinib

Recent research published in The New England Journal of Medicine explored the use of Ibrutinib, a newly approved targeted drug, as a treatment for CLL. Developed by Pharmacyclics and Janssen Biotech, Ibrutinib has been sanctioned by the U.S. Food and Drug Administration for this purpose. The phase 3 clinical study assessed the drug’s efficacy, both alone and in combination with other intravenous treatments.

Study Details

The clinical trial involved 547 participants from various medical centers across the United States and Canada, conducted between December 2013 and May 2016. All participants were over the age of 65, with a median age of 71. They were randomly assigned to receive either conventional chemotherapy, Ibrutinib, or Ibrutinib combined with traditional chemotherapy.

Results of the Trial

After a follow-up period of two years, 87 percent of patients treated with Ibrutinib were alive without any disease progression, compared to 74 percent of those receiving standard chemotherapy. Additionally, Ibrutinib demonstrated fewer side effects, with only 17 percent of patients experiencing irregular heartbeat issues. Overall, Ibrutinib was found to be superior to conventional chemoimmunotherapy in terms of progression-free survival, and further studies are ongoing to explore combined targeted therapies.

Conclusion

The findings from this study highlight the potential of Ibrutinib as an effective treatment option for older patients with untreated CLL, paving the way for improved therapeutic strategies in managing this common form of leukemia.

Reference

Woyach, J.A. et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. The New England Journal of Medicine, 2018;79:26. DOI: 10.1056/NEJMoa1812836.